Lawsuit Filed Against Rocket Pharmaceuticals for Securities Fraud

Levi & Korsinsky, LLP has filed a securities class action lawsuit against Rocket Pharmaceuticals, Inc. (RCKT) on behalf of shareholders who purchased the company’s securities between June 29, 2020, and March 29, 2021.

The lawsuit alleges that Rocket Pharmaceuticals made false and misleading statements regarding the efficacy of its gene therapy treatments and its prospects for regulatory approval. The company’s stock price plummeted after it was revealed that Rocket’s experimental gene therapy failed to meet its primary and secondary endpoints in a clinical trial.

Shareholders who suffered losses as a result of investing in Rocket Pharmaceuticals are encouraged to contact Levi & Korsinsky for more information about their legal rights and options. The firm is dedicated to protecting the interests of shareholders and holding companies accountable for their actions.

Levi & Korsinsky is a leading securities litigation firm with a track record of successfully representing investors in class action lawsuits. The firm is committed to seeking justice for shareholders who have been harmed by corporate fraud or misconduct. Shareholders can learn more about the lawsuit and how to participate by visiting Levi & Korsinsky’s website or contacting the firm directly.